Glioblastoma Immunotherapy Advancement with Nivolumab and Relatlimab
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
November 25, 2024
End Date
March 11, 2027
Awarded By
Bristol-Myers Squibb Company
Start Date
November 25, 2024
End Date
March 11, 2027